

A decorative element consisting of a grid of small blue dots arranged in four rows and ten columns.

SCOPE FLUIDICS

1Q2025 update

A decorative element consisting of a series of grey zigzag lines.

22 May 2025

Niniejsza prezentacja (“Prezentacja”) zawiera podstawowe informacje dotyczące Scope Fluidics S.A. („Spółka”) oraz grupy kapitałowej Scope Fluidics S.A. („Grupa”).

Prezentacja została przygotowana wyłącznie w celu przedstawienia podstawowych informacji o Grupie i jej działalności. Prezentacja nie przedstawia pełnych danych dotyczących działalności Grupy, jej kondycji finansowej, sytuacji majątkowej i prawnej, które mogą być wymagane w celu podjęcia decyzji inwestycyjnej dotyczącej Grupy lub instrumentów finansowych podmiotów do niej należących. Spółka podjęła środki w celu zapewnienia, że zaprezentowane dane są w pełni wiarygodne, jakkolwiek nie mogą i nie powinny być jako takie traktowane. Wszystkie przewidywania, opinie i projekcje zawarte w Prezentacji łącznie z projekcjami, opiniami oraz przewidywaniami Spółki zostały przygotowane w ramach wykonywania zwykłych czynności analitycznych i nie należy ich traktować jako informacji zatwierdzonych przez jakikolwiek podmiot trzeci. Mimo podjęcia środków mających na celu zapewnienie, że fakty wskazane w Prezentacji są prawdziwe, a przewidywania, opinie i prognozy są wiarygodne i zasadne, Spółka nie weryfikowała ich kompletności ani trafności. W konsekwencji ani Spółka ani żaden z jej akcjonariuszy i doradców, ich podmiotów powiązanych, członków organów i pracowników nie ponosi odpowiedzialności, na jakiegokolwiek podstawie, za treści zawarte w Prezentacji.

Przy podejmowaniu decyzji inwestycyjnych, czy też działając w jakimkolwiek innym celu, nie należy opierać się na informacjach zawartych w Prezentacji, w tym w zakresie ich prawdziwości, rzetelności i zupełności. Żaden z wymienionych wyżej podmiotów nie uznaje swojej odpowiedzialności na jakiegokolwiek podstawie za jakiegokolwiek szkody wynikające z użycia niniejszego dokumentu i informacji w nim zawartych. Oświadczeń zawartych w Prezentacji nie należy traktować jako zapewnień lub gwarancji Spółki lub jako zobowiązań czy obietnic dotyczących przyszłych wyników finansowych czy operacyjnych Grupy. Treść Prezentacji nie stanowi ani nie powinna być traktowana jako porada inwestycyjna, prawna lub podatkowa. Odbiorca Prezentacji powinien samodzielnie uzyskać odpowiednią poradę inwestycyjną, prawną bądź podatkową.

Prezentacja nie stanowi oferty, w szczególności w rozumieniu ustawy z dnia 29 lipca 2005 roku o ofercie publicznej i warunkach wprowadzania instrumentów finansowych do zorganizowanego systemu obrotu oraz o spółkach publicznych (Dz.U. t.j. 2013.1382 z późn. zm.) lub ustawy z dnia 23 kwietnia 1964 r. kodeks cywilny (Dz.U. t.j. 2014.121 z późn. zm.), rekomendacji lub zaproszenia do zapisywania się lub zakupu obligacji. Ani Prezentacja ani żadna jej część nie stanowi jakiegokolwiek umowy lub jakiegokolwiek zobowiązania dotyczącego wykonania takiej umowy.

Spółka zastrzega sobie prawo do dokonania zmian lub uzupełniania Prezentacji w każdym momencie, jakkolwiek nie jest do tego zobowiązana, podobnie jak nie jest zobowiązana do dokonywania jakichkolwiek aktualizacji lub poprawek treści Prezentacji, ani do dostarczania dodatkowych informacji o Spółce ani Grupie.

UNIQUE COMBINATION OF COMPETENCIES IN TECHNOLOGY, OPERATIONS AND FINANCIAL AREAS

MANAGEMENT BOARD OF SCOPE FLUIDICS



MARCIN IZYDORZAK

VICE PRESIDENT

- Co-founder of Scope Fluidics
- Responsible for clinical trials, IP, production and regulatory areas
- Gained experience in technology companies, scientific institutes and pharmaceutical companies



PROF. PIOTR GARSTECKI

CEO

- Co-founder of Scope Fluidics
- Responsible for development of innovative technologies and building the organization
- Experience in scientific and technological projects in Poland and in the USA, specialized in soft matterphysics and microfluidic technologies



SZYMON RUTA

VICE PRESIDENT, CFO

- Responsible for financial division, investor relations and M&A transactions
- Experienced in managing of capital groups, cooperation with capital markets and execution of M&A transactions

Venture Studio - our values and vision for success

We address **global challenges in healthcare** and develop technologies with real, global impact.

We aim at +USD 10⁹ markets and develop technologies that can readily be leveraged by large, multinational and global med-tech operators.

We develop companies as attractive acquisition targets for global strategic investors with valuations in multiples of USD 100 mln.



VENTURE STUDIO BUSINESS MODEL

Corporate structure supports execution of M&A transactions





Each project in Scope Fluidics' Group is **developed in a separate, legal entity (SPV)**



Each subsidiary is focused on the R&D activities and has the full ownership of all the IP relevant to its project, employment, commercial contracts, and all relevant certifications



Scope Fluidics provides SPVs with back-office functions, such as HR, finance, reporting, legal, regulatory, etc.




PCR|ONE – from idea to commercialization

Curiosity Diagnostics developing **PCR|ONE**,
automated point-of-care PCR system with a high
multiplexing potential and **time-to-result under 20 min**

- ✓ Idea
- ✓ MVP
- ✓ IP protection
- ✓ QMS/ISO
- ✓ Certification
- ✓ Product
- ✓ Cost-effective
- ✓ Ready for transfer to manufacturing




- **3 Letters of Intent** from key industry players
- **~12 months** of intensive process and negotiations




USD 130m

total transaction value



BACTEROMIC

User-centric design and compliance



Simple and standardized AST workflow

Diluted **Isolate / PBC** solution is pipetted onto the cartridge



<1 min

Up to 10 cartridges in parallel, automatically filled & sealed



<5 min

Automated AST on up to **60 cartridges**



<6 hours

AST results in LIS



ACTIONABLE AST RESULTS FOR GUIDED ANTIBIOTIC THERAPY

NO NEED FOR ID BEFORE TEST – can be provided during or after AST for results interpretation


Addressing critical global healthcare challenge

Opportunity to serve a growing and evolving market demand

Isolates

Global AST diagnostics market (USD bn)


- "AMR could cause 10 million deaths annually by 2050"
(Jim O'Neill Report)
- "Currently, AMR is linked to 1.27 million deaths each year"
(Chris Murray, The Lancet, 2022)



Positive Blood Cultures

Global sepsis diagnostics market (USD bn)

- "Sepsis accounts for 20% of all deaths globally"
(Global Sepsis Alliance, 2020).
- "Rapid AST is critical for targeted sepsis therapies."



Fortune Business Insights, CoherentMarketInsights, Mordor Intelligence, Grand View Research

Automated AST market

Standard AST (16-24 h)

MATURE MARKET



Vitek



BECKMAN
COULTER

MicroScan WalkAway

ThermoFisher
SCIENTIFIC

Sensititre



BD

Phoenix

Rapid AST (<8 h)

EMERGING MARKET

Selux^{DX}

ACCELERATE
DIAGNOSTICS

DEVELOPING MARKET

Q-LINEA



iFAST



gradientech

Selux^{DX}



ACCELERATE
DIAGNOSTICS



QUANTAMATRIX

FAST^{inov}
Next Generation
Antimicrobial Resistance Technologies

No market

Isolates

Positive Blood
Cultures

**AST market needs future-proof, informative,
rapid and cost-effective system**

**that offers synergies across
isolate and PBC market segments**

AST market trends

Isolates

- **high** throughput
- **low** price
- slow is OK

requirement
for rapid

- high throughput
- low price
- **rapid**

Positive Blood Cultures

- low throughput
- high price
- must be **rapid**

requirement
for cost & throughput

- **high** throughput
- **low** price
- rapid

First system to address both markets

Isolates

- high throughput
- low price
- slow is OK

requirement
for rapid



BACTEROMIC

- high throughput
- low price
- rapid



Positive Blood Cultures

- low throughput
- high price
- must be rapid

requirement
for cost & throughput

Ideal solution for evolving AST market



- rapid AST
- high-throughput
- one panel for all bacteria
- one box for PBC and isolates
- broad antibiotic menu on a single card
- true MIC
- cost-effective manufacturing

Potential for Bacteromic to rival the global AST space

Technology excellence – best AST offering on the market

Overall scoring	63	57	39	37	35	35	34	32	30
System	Bacteromic								
Future-proof real estate (wells)	5	4	3	4	3	3	1	3	3
PBC & Isolates relevance	5	5	1	1	1	1	1	1	1
PBC offering attractiveness	5	5	3	4	3	3	3	4	3
Isolates offering attractiveness	5	5	3	1	1	1	1	1	1
Antibiotics menu	5	5	3	4	3	3	3	4	1
Quantitative MIC (dilutions)	5	5	2	5	2	2	5	2	3
Analyzer's capacity (panels)	5	5	1	1	1	1	1	1	1
Time of AST	5	5	5	5	5	5	5	5	5
Manual procedure	4	5	4	5	5	3	4	3	1
GN/GP versatility	5	5	4	2	4	2	2	2	2
Cost of panels	4	4	4	3	3	5	4	4	5
Cost of system (price per slot)	5	1	3	1	1	3	3	1	3
Hardware's capacity-to-footprint @ 100cm	5	3	3	1	3	3	1	1	1
	\$18m Capital used	\$>160m Capital raised	\$>200m Capital raised	\$>60m Capital raised	\$>55m Capital raised			\$425m M&A	

January
San Francisco

JP Morgan
Healthcare Conference
J.P.Morgan

April
Wiena

ECCMID
ECCMID

June
London

JP Morgan
Healthcare Symposium
J.P.Morgan

July
Chicago

ADLM
ADLM Association for
Diagnostics &
Laboratory Medicine™

November
London


Jefferies
Healthcare Conference
Jefferies



Discovery & new projects

The process of creating new Special Purpose Vehicles

Systemic selection and development of new projects



AI-driven platform with a life-saving device for early stroke detection



PROBLEM

Strokes often go undetected for hours, preventing timely treatment and contributing to over **12 million stroke-related deaths annually, approx. 100 mln people at high stroke risk and 1bn at increased risk**. With a projected 32% increase, the economic impact surpasses **\$450 billion**.

1

SOLUTION

Our device leverages AI to analyze subtle signal changes, enabling early stroke detection and tracking of hemodynamic parameters.

2

IMPACT

This technology empowers treatment within the critical **4.5-6 hour window, potentially preventing 80% of stroke related consequences and saving the lives of high risk patients**.

3

MARKET OPPORTUNITY

\$4.0
billion TAM

~10.0%
CAGR

4

Analysis of M&A transactions brings promising opportunities

CLOSED M&A TRANSACTIONS

TERMINATED

	 wearable cardiac monitors \$925M + USD 300m in milestone payments	 wearable cardiac monitors \$375M + undisclosed milestone payments	 health monitoring platform \$400M	 invasive heart attack warning system \$195M
Acquisition date	2021	2021	2021	2023
Buyer	Boston Scientific	Hillrom (Baxter Group)	Best Buy	BIOS Acquisition Corp.
Revenue	USD 158m	USD 54m	USD 20m	USD 1.1m
Certification	FDA & CE	FDA & CE	FDA	FDA

AI-driven platform with a life-saving device for early stroke detection



PROBLEM

The global prevalence of diabetes is steadily increasing, with projections indicating a significant rise, potentially reaching **643 million cases within the next five years**.

1



SOLUTION

Early detection of metabolic syndrome risk through monitoring key biomarkers for insulin resistance and type 2 diabetes.

2



IMPACT

Metabolic imbalance poses a significant health risk, with **1 in 10 individuals affected by diabetes and a life lost to the disease every 5 seconds**. Early detection and treatment of abnormal glycemic trends can prevent up to 60% of diabetes cases.

3



MARKET OPPORTUNITY

\$23.0
billion TAM

20.0%
CAGR

4



ANALYSIS OF M&A TRANSACTIONS BRINGS PROMISING OPPORTUNITIES

CLOSED M&A TRANSACTIONS

	 Early CGM development \$3.7B	 Early CGM development \$1.2B + undisclosed milestone payments	 CGM \$1.6B	 CGM undisclosed
Acquisition date	2001	2003	2022	2023
Buyer	Medtronic	Roche	Owens&Minor	Abbott
Revenue	USD 350 M	USD 217.75 M	USD unknown	USD 25 M
Certification	FDA (after acquisition)	FDA & CE (after acquisition)	unknown	FDA

[1] thepharmaletter.com ; [2] nytimes.com; [3] massdevice.com; [4] drugdeliverybusiness.com

Where do we want to be?

1

By the end of 2025

having at least five new projects in the portfolio,
including **at least two**
in the form of **special purpose vehicles**

2

By the end of 2028

Closing at least two
strategic transactions

3

In the period of 2029-2033

readiness to carry out **at least one**
strategic transaction on an annual average

STRATEGIC TRANSACTIONS:

1. **Sale of all shares in special purpose vehicles** developing breakthrough technologies to strategic industry investors
2. **Sale of part of existing or newly created shares in Special Purpose Vehicles** developing breakthrough technologies to strategic industry or financial investors

1

By the end of 2025

having at least five new projects in the portfolio,
including **at least two**
in the form of **special purpose vehicles**

Goal no 1 achieved in
January 2025

2

By the end of 2028

Closing at least two
strategic transactions

3

In the period of 2029-2033

readiness to carry out **at least one**
strategic transaction on an annual average

INVESTMENT

- Maximizing the value of BACTEROMIC transaction
- Developing second potential project to M&A readiness

Getting the size and traction to deliver the goal no 3

15 Years of Systematic Growth: Building an Even Stronger Future

From a 10k PLN start-up to a largest med-tech venture studio in CEE

2010 Founded for PLN 10k

2010-2015 Two generations of BlueBox, EUR 6m turnover

2012 Launch of Curiosity Diagnostics

2017 Founding of the Bacteromic company

2017 New Connect listing

2022 Development and sale of PCR I ONE

2023 Listing on the main market of WSE

2023 Launch of Scope Discovery

2024 Launch of Edocera and Hybolic SPVs

2025 BACTEROMIC in IVDR certification process, planned market launch

The logo for PCR I ONE, featuring the text "PCR I ONE" in a black, stylized, blocky font. A vertical red line is positioned between the "I" and the "ONE".

SCOPE FLUIDICS

**Financial track record – outstanding return on investment
and dynamic outlook for future developments.**

Raised
~USD 10m
(< 50 mPLN)



USD 130m revenue from sales of PCR I One

USD 100m market cap (10x since IPO)

USD 50m dividend payed out in 2023

BACTEROMIC developed to the pre IVDR stage

Stable cash position




**Bacteromic,
Venture Studio
with yearly
exits.**

NEXT STEPS
Plans




Key value inflection points in MedTech development

**BACTEROMIC**

GROWING MARKET NEED FOR
RAPID HIGH-THROUGHPUT AST FOR PBC AND ISOLATES

Benchmark transactions in diagnostics space



Rapid AST for PBC



2019 - Minority investment
2021 - Distribution exclusivity
2022 - Acquisition for USD 425m

Rapid AST for UTI (Point of Care)



2020 - Minority investment
2022 - CE-IVD obtained
2022 - Acquisition (undisclosed value)

Maximizing value in parallel with ongoing M&A process

2025

- A "fast detection" software for rapid bacterial growth detection and antibiotic susceptibility testing within 8 hours or less;
- A Rapid UNI Panel (based on the current UNI Panel) identifying up to ~31 antibiotics and compatible with the fast detection software;
- A Rapid BSI (PBC)* Panel for bloodstream infection diagnostics, delivering results within 8 hours and focused on key antibiotics for treating common sepsis-related pathogens. This panel will be developed exclusively for use with the fast detection software
- Launch of production line in Spain

2026

- A "fast detection" software for rapid bacterial growth detection and antibiotic susceptibility testing within 8 hours or less
- UNI MAX Panel – an extended version of the UNI Panel, planned to cover around 40 antibiotics and one ESBL mechanism;
- Rapid UNI MAX Panel – the UNI MAX Panel integrated with the fast detection software.
- Continuation of the work on optimizing the analyzer and filling machine.
- Start of the organic sale of the product in CEE and Middle East

2027

- Doubling of the production capacity by 2027
- Start of sale of the product in UK, Western Europe and USA

CERTIFICATION TARGETS

- **End of 2025:** IVDR compliance certificate for the BACTEROMIC system with the UNI Panel and the current version of the interpreter.
- **2026:** IVDR certification for the BACTEROMIC system with the following panels: Rapid UNI, Rapid BSI, and UNI MAX
- **2027:** IVDR certification for the Rapid UNI MAX Panel
- **2027:** FDA certification for the BACTEROMIC system with two panels: the Rapid UNI Panel and the Rapid BSI Panel



Investment in the future

SCOPE DISCOVERY

2-3 additional SPVs launched - 4-5 SPVs in the portfolio at the end of 2027

SCOPE FLUIDICS

Activities within the Scope necessary for the proper and efficient operation of the Group in 2025-2027

EDOCERA

2025 - verification of selected technologies expected to be completed, start of R&D works on the prototype

2025 - beginning of developing the software to operate the device

2026 - prototype ready

2027 - software ready

2027 - beginning of work on the first version of the device, which will undergo market validation and, upon completion, will be submitted for certification

2026-2027 - market validation activities

2027 - filing the first patent application or utility model protection


HYBOLIC

2025 - confirmation the effectiveness of the selected insulin detection method.

2026 - integrating the chosen methods and techniques to create a fully integrated sensor-measurement system and preclinical studies to verify the hypothesis regarding the diagnostic and predictive value of insulin measurement.

2027 - work on the prototype expected to be completed, beginning of the development of the final device.

End of 2027 - all key components of the product developed under the HYBOLIC project are to be integrated into a coherent, functioning system



Multiple potential sources of financing

STRATEGIC TRANSACTIONS

- Recommendation for keeping profit from PCR|ONE milestone settlement

GRANTS

- Long processes with limited control
- Valuable supplemental financing

VENTURE DEBT

- Elevated costs
- Restrictions related to this form of financing

TARGET CAPITAL

- Stronger negotiation position for Strategic Transaction
- Flexible tools for investment opportunities

THANK YOU!



INVESTOR RELATIONS

relacjeinwestorskie@scopefluidics.com

